13F filer · CIK 351051 ↗
Massachusetts Institute of Technology
You are looking at Q3 2020. See the latest, Q2 2026 →
Reported value
$45.1M
−34% on the quarter before
Positions
6
2 new · 4 sold out
Top 10
100.0%
of the value
Est. gain
+$2.2M
on stocks held all quarter
Est. return
+5.4%
on those stocks since Q2 2020
Positions as of Sep 30, 2020, from Massachusetts Institute of Technology's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2020. Striped tiles are options.
Largest buys
Since Q2 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Crispr Therapeutics Ag~$1.9MNew · 0.0% → 4.1%+22,162 shares
- Apple~$348,000New · 0.0% → 0.8%+3,009 shares
Largest sells
Since Q2 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Ishares Tr~$13.3MSold out · 19.6% → 0.0%−42,945 shares
- Shopify Inc~$7.0MSold out · 10.3% → 0.0%−7,399 shares
- Upwork Inc~$5.6MSold out · 8.3% → 0.0%−390,902 shares
- Iveric Bio Inc~$867,750Cut · 2.3% → 1.9%−153,870 shares
- Finvolution Group~$526,000Sold out · 0.8% → 0.0%−290,422 shares
Holdings
As of Sep 30, 2020. Changes are in shares against Jun 30, 2020, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Boston Omaha CorpCOM · shares 0% · price 0.0% | 73.5% | $33.1M | $0.00 | ||||||||
| SalesforceCOM · shares 0% · price +34.2% | 18.6% | $8.4M | +$2.1M | ||||||||
| Crispr Therapeutics AgNAMEN AKT · shares New | 4.1% | $1.9M | — | ||||||||
| Iveric Bio IncCOM · shares −50% · price +10.5% | 1.9% | $870,000 | +$82,982 | ||||||||
| Textron IncCOM · shares 0% · price 0.0% | 1.2% | $527,000 | $0.00 | ||||||||
| AppleCOM · shares New | 0.77% | $348,000 | — | ||||||||
| Total · 6 positions | 100% | $45.1M | +$2.2M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2020 to Q3 2020: 4 stocks held throughout, up $2.2M (+5.4%).
- Salesforce+$2.1M+34%
- Iveric Bio Inc+$82,982+11%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | $732.6M+27% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $577.0M−23% | SEC ↗ |
| Q4 2025 | Feb 12, 2026 | $753.3M−18% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $920.4M−8% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $995.5M+41% | SEC ↗ |
| Q1 2025 | May 14, 2025 | $707.2M+0% | SEC ↗ |
| Q4 2024 | Feb 12, 2025 | $705.1M−6% | SEC ↗ |
| Q3 2024 | Nov 14, 2024 | $749.0M+17% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $638.9M+14% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $558.2M+3% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $539.6M−7% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $581.2M−13% | SEC ↗ |
| Q2 2023 | Aug 14, 2023 | $669.2M+5% | SEC ↗ |
| Q1 2023 | May 4, 2023 | $639.6M+6% | SEC ↗ |
| Q4 2022 | Feb 10, 2023 | $602.4M+2% | SEC ↗ |
| Q3 2022 | Nov 3, 2022 | $588.0M+26% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $466.3M−26% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $626.9M−15% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $738.1M+727% | SEC ↗ |
| Q4 2020 | Feb 5, 2021 | $89.2M+98% | SEC ↗ |
| Q3 2020 | Nov 12, 2020 | $45.1M−34% | SEC ↗ |
| Q2 2020 | Aug 10, 2020 | $68.0M+52% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $44.8M−43% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $78.7M−16% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $94.2M−10% | SEC ↗ |
| Q2 2019 | Aug 9, 2019 | $104.4M−11% | SEC ↗ |
| Q1 2019 | May 14, 2019 | $117.6M+1% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $117.1M | SEC ↗ |